Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 6/20 | 0.57 |
| ▸ | CDK2 | P24941 | 6/20 | 0.57 |
| ▸ | CDK1 | P06493 | 4/20 | 0.54 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.54 |
| ▸ | KDM5A | P29375 | 1/20 | 0.44 |
| ▸ | CDK14 | O94921 | 2/20 | 0.43 |
| ▸ | CCNY | Q8ND76 | 2/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13996264 | 1.00 | CCNA2 (0.57) | CCNA2CDK2CDK1CCNB1KDM5A | |
| SCHEMBL8219404 | 1.00 | CCNA2 (0.57) | CCNA2CDK2CDK1CCNB1KDM5A | |
| SCHEMBL13993615 | 0.91 | CCNA2 (0.56) | CCNA2CDK2CDK1CCNB1KDM5A | |
| SCHEMBL8214922 | 0.91 | CDK2 (0.64) | CCNA2CDK2CDK1CCNB1CCNA1 | |
| SCHEMBL959133 | 0.90 | CDK2 (0.69) | CCNA2CDK2CDK1CCNB1KDM5A | |
| SCHEMBL12000425 | 0.90 | CCNA2 (0.54) | CCNA2CDK2CDK1CCNB1KDM5A | |
| SCHEMBL8222518 | 0.89 | CCNA2 (0.55) | CCNA2CDK2CDK1CCNB1KDM5A | |
| SCHEMBL13996348 | 0.89 | CDK5 (0.45) | CCNA2CDK2CDK1CCNB1CDK14 | |
| SCHEMBL8263075 | 0.87 | CCNA2 (0.52) | CCNA2CDK2CDK1CCNB1KDM5A | |
| SCHEMBL8262275 | 0.86 | CDK2 (0.56) | CCNA2CDK2CDK1CCNB1CDK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651612-B9 | 3,4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASES (CDK) AND GLYCOGEN SYNTHASE KINASE-3 (GSK-3) MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2012-09-05 | — | — | EP | disclosed |
| EP-1651612-B1 | 3,4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASES (CDK) AND GLYCOGEN SYNTHASE KINASE-3 (GSK-3) MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2012-04-11 | — | — | EP | disclosed |
| EP-2256106-A1 | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators | Astex Therapeutics Limited (GB) | 2010-12-01 | — | — | EP | disclosed |
| US-20080306069-A1 | Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S | ASTEX THERAPEUTICS LIMITED (UK) | 2008-12-11 | — | — | US | disclosed |
| WO-2008007113-A2 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306069-A1 | Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S | GSK3A, CDK11A, CDK1 | CCNA2 20/4885CDK2 4/4885CDK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.